Drug repurposing for rare diseases: an integrated data driven approach
Jabe Wilson; Megan Golden
About this talk
Pharma R&D for rare diseases is, itself, rare, because patient populations are perceived as insufficient to deliver ROI. Drug repurposing eliminates the expensive process of discovering a completely new compound, shortens the time that is needed to reach the patients, and ensures a higher success rate.
Elsevier and Pistoia Alliance organized a drug-repurposing datathon, with Cures Within Reach and Mission: Cure being the consulting organizations. The objective was to identify repurposable drug candidates for chronic pancreatitis – a rare disease that affects about 1 million people globally, and currently doesn’t have an approved treatment. As a result, this datathon identified 4 drug candidates in 30-60 days. They were reviewed and approved by the expert panel, pending further clinical trials by Mission:Cure.
This webinar will talk about this unique non-profit and private collaborative datathon, using Entellect, an AI-powered technology platform for identifying repurposable drug candidates for chronic pancreatitis.
The topics will include:
- Introduction to datathon
- Predictive analytics for drug repurposing - needs and challenges
- Established strategy and workflow
- Outcome and impact
- Update to the clinical trial progress
Jabe Wilson, Global Commercial Director, Data and Analytics, Elsevier
Megan Golden, co-founder and co-director, Mission: Cure